Orasure Technologies (OSUR)
NASDAQ:OSUR
OSUR Stock Chart & Stats
$2.38
-$0.09(-2.38%)
At close: 4:00 PM EST
$2.38
-$0.09(-2.38%)
Day’s Range― - ―
52-Week Range$2.08 - $3.82
Previous CloseN/A
Volume226.53K
Average Volume (3M)771.42K
Market Cap
$212.91M
Enterprise Value$234.89M
Total Cash (Recent Filing)$199.28K
Total Debt (Recent Filing)$13.20M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 13, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding69,126,175
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue2.04
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda-3.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$118.95M
Bulls Say, Bears Say
Bulls Say
Strong Cash Position, Zero DebtA large cash balance and no debt provide a durable financial runway to fund FDA submissions, near-term launches, and working capital while the company pursues its multi-year path to operating cash‑flow breakeven. This reduces refinancing risk and supports strategic optionality during recovery.
Manufacturing Consolidation & Margin SupportConsolidating manufacturing and internalizing sample-management volumes materially lowers unit costs and increases fixed-cost absorption as volumes recover. This structural shift improves gross-margin sustainability and creates operating leverage when utilization rises from current low levels.
Near-term FDA Submissions And Product PipelineRegulatory clearances would open a sizable OTC and at‑home STI market (company cites CT/NG TAM >$1.5B), diversifying revenue toward decentralized, higher‑utility products. Successful approvals would be structural demand drivers, improving scale, margins, and utilization into H2 2026 and beyond.
Bears Say
Steep Revenue Decline And Weakened ProfitabilityA pronounced revenue contraction (multi-year decline from 2023) erased scale benefits and turned prior net margins positive into significant losses. Durable profitability depends on a meaningful top-line recovery; absent sustained demand, fixed costs and legacy scale inefficiencies will pressure returns.
Negative Operating Cash Flow And Cash BurnOperating cash flow turned negative in 2025 despite a strong starting cash balance, and management targets breakeven only by 2027. Continued cash burn can erode the current cash runway if product rollouts or recoveries slip, forcing tougher capital-allocation tradeoffs or external financing.
Funding And Regulatory Timing RiskRecovery relies on external public‑health funding and timely FDA reviews. Implementation problems and regulatory timing uncertainty create structural revenue volatility and delay margin improvements tied to higher utilization and new-product ramps, increasing execution risk over the medium term.
Orasure Technologies News
OSUR FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $3.82 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is $212.91M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is May 13, 2026 which is in 28 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on Feb 25, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.065.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.22.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 69,126,175 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
OSUR Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 14.1K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.53%
12-Months-Change
Fundamentals
Return on Equity
-18.58%
Trailing 12-Months
Asset Growth
-15.95%
Trailing 12-Months
Company Description
Orasure Technologies
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.
OSUR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights clear progress on strategic priorities: revenue slightly beat guidance midpoint, meaningful improvement in gross margins year-over-year, strong cash position with no debt, two significant FDA submissions targeting midyear launches, tangible international expansion (Canada launch, nearshoring in Africa) and early success integrating BiMedomics. Offsetting these positives are sizable operating losses and negative operating cash flow, a multi-year timeline to return to operating cash flow breakeven (target 2027), lingering funding-related headwinds in international public-health markets, regulatory timing uncertainty for new product launches, and under-utilized capacity that makes margin improvement contingent on revenue ramp. Overall, the call conveys cautious optimism grounded in a solid balance sheet and promising near-term product catalysts but tempered by execution risk and the need for top-line recovery to fully realize margin and cash-flow benefits.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
5.49% Insiders
16.13% Mutual Funds
32.86% Other Institutional Investors
32.86% Public Companies and
Individual Investors